<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>REGITINE- phentolamine mesylate injection, powder, lyophilized, for suspension </strong><br>Novartis Pharmaceuticals Corporation<br></p></div>
<h1>Regitine<span class="Sup">®</span>
</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2"></a><p></p>
<h1></h1>
<p class="First">C98-25<br>665490</p>
<p><span class="Bold">     
	Regitine</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold"></span></p>
<p><span class="Bold">     
	phentolamine mesylate for injection, USP</span></p>
<p><span class="Bold">     
	Vials</span></p>
<p><span class="Bold">     
	Rx only</span></p>
<p><span class="Bold">     
	Prescribing Information</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-3"></a><p></p>
<h1><span class="Bold">DESCRIPTION</span></h1>
<p class="First">Regitine, phentolamine mesylate for injection, USP, is an antihypertensive, available in vials for intravenous and intramuscular administration.  Each vial contains phentolamine mesylate USP, 5 mg, and mannitol USP, 25 mg, in sterile, lyophilized form.</p>
<p>Phentolamine mesylate is 4,5-dihydro-2-[N-(<span class="Italics">m</span>-hydroxyphenyl)-N-(<span class="Italics">p</span>-methylphenyl) aminomethyl]-1<span class="Italics">H</span>-imidazole 1:1 methanesulfonate, and its structural formula is</p>
<p><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6DB10859-2A3F-4782-AC33-94300463658F&amp;name=regitine-figure-02.jpg"></p>
<p>Phentolamine mesylate for injection, USP, is a white or off-white, odorless crystalline powder with a molecular weight of 377.46. Its solutions are acid to litmus. It is freely soluble in water and in alcohol, and slightly soluble in chloroform. It melts at about 178ºC.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-4"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY </span></h1>
<p class="First">Regitine produces an alpha-adrenergic block of relatively short duration. It also has direct, but less marked, positive inotropic and chronotropic effects on cardiac muscle and vasodilator effects on vascular smooth muscle.</p>
<p>Regitine has a half-life in the blood of 19 minutes following intravenous administration. Approximately 13% of a single intravenous dose appears in the urine as unchanged drug.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE</span></h1>
<p class="First">Regitine is indicated for the prevention or control of <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">hypertensive episodes</span> that may occur in a patient with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> as a result of stress or manipulation during preoperative preparation and surgical excision.</p>
<p>Regitine is indicated for the prevention or treatment of dermal <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> and <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">sloughing</span> following intravenous administration or <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> of norepinephrine.</p>
<p>Regitine is also indicated for the diagnosis of <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> by the Regitine blocking test.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS</span></h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>, history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, coronary insufficiency, angina, or other evidence suggestive of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>; <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to phentolamine or related compounds.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<h1><span class="Bold">WARNINGS</span></h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4249605" conceptname="Spasm of cerebral arteries">cerebrovascular spasm</span>, and cerebrovascular occlusion have been reported to occur following the administration of Regitine, usually in association with marked <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotensive episodes</span>.</p>
<p>For screening tests in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, the generally available urinary assay of catecholamines or other biochemical assays have largely replaced the Regitine and other pharmacological tests for reasons of accuracy and safety. None of the chemical or pharmacological tests is infallible in the diagnosis of <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>. The Regitine blocking test is not the procedure of choice and should be reserved for cases in which additional confirmatory evidence is necessary and the relative risks involved in conducting the test have been considered.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1><span class="Bold">PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-8.1"></a><p></p>
<h2><span class="Bold">General</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> may occur with the use of Regitine or other alpha-adrenergic blocking agents. When possible, administration of cardiac glycosides should be deferred until cardiac rhythm returns to normal.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-8.2"></a><p></p>
<h2><span class="Bold">Drug Interactions</span></h2>
<p class="First">See DOSAGE AND ADMINISTRATION, Diagnosis of <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>,<span class="Italics"> Preparation</span>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-8.3"></a><p></p>
<h2><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></h2>
<p class="First">Long-term carcinogenicity studies, mutagenicity studies, and fertility studies have not been conducted with Regitine.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.4"></a><p></p>
<h2><span class="Bold">Pregnancy Category C</span></h2>
<p class="First">Administration of Regitine to pregnant rats and mice at oral doses 24-30 times the usual daily human dose (based on a 60-kg human) resulted in slightly decreased growth and slight skeletal immaturity of the fetuses. Immaturity was manifested by increased incidence of incomplete or unossified calcanei and phalangeal nuclei of the hind limb and of incompletely ossified sternebrae. At oral doses 60 times the usual daily human dose (based on a 60-kg human), a slightly lower rate of implantation was found in the rat. Regitine did not affect embryonic or fetal development in the rabbit at oral doses 20 times the usual daily human dose (based on a 60-kg human). No teratogenic or embryotoxic effects were observed in the rat, mouse, or rabbit studies.</p>
<p>There are no adequate and well-controlled studies in pregnant women. Regitine should be used during pregnancy only if the potential benefit  justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.5"></a><p></p>
<h2><span class="Bold">Nursing Mothers</span></h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Regitine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.6"></a><p></p>
<h2><span class="Bold">Pediatric Use</span></h2>
<p class="First">See DOSAGE AND ADMINISTRATION.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-9"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS</span></h1>
<p class="First">Acute and prolonged <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotensive episodes</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> have been reported. In addition, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal stuffiness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may occur.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1><span class="Bold">OVERDOSAGE</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2><span class="Bold">Acute Toxicity</span></h2>
<p class="First">No <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to acute <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> with Regitine have been reported.</p>
<p>Oral LD<span class="Sub">50</span>’s (mg/kg): mice, 1000; rats, 1250.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2><span class="Bold">Signs and Symptoms</span></h2>
<p class="First">Overdosage with Regitine is characterized chiefly by cardiovascular disturbances, such as <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and possibly <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>. In addition, the following might occur: excitation, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, pupillary contraction, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>; <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2><span class="Bold">Treatment</span></h2>
<p class="First">There is no specific antidote.</p>
<p>A decrease in blood pressure to dangerous levels or other evidence of shocklike conditions should be treated vigorously and promptly. The patient’s legs should be kept raised and a plasma expander should be administered. If necessary, intravenous infusion of norepinephrine, titrated to maintain blood pressure at  the normotensive level, and all available supportive measures should be included. Epinephrine should not be used, since it may cause a paradoxical reduction in blood pressure.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION</span></h1>
<p class="First"><span class="Italics">The reconstituted solution should be used upon preparation and should not be stored.</span></p>
<p><span class="Italics">Note:</span>  Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
<p><span class="Bold">1. Prevention or control of <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">hypertensive episodes</span> in the patient with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>.</span></p>
<p>For preoperative reduction of elevated blood pressure, 5 mg of Regitine (1 mg for children) is injected intravenously or intramuscularly 1 or 2 hours before surgery, and repeated if necessary.</p>
<p>During surgery, Regitine (5 mg for adults, 1 mg for children) is administered intravenously as indicated, to help prevent or control paroxysms of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, or other effects of epinephrine <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>. (Postoperatively, norepinephrine may be given to control the <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> that commonly follows complete removal of a <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>.)</p>
<p><span class="Bold">2. Prevention or treatment of dermal <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> and <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">sloughing</span> following intravenous administration or <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> of  norepinephrine.</span></p>
<p><span class="Italics">For Prevention:  </span>10 mg of Regitine is added to each liter of solution containing norepinephrine. The pressor effect of norepinephrine is not affected.</p>
<p><span class="Italics">For Treatment:</span>  5-10 mg of Regitine in 10 mL of saline is injected into the area of <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> within 12 hours.</p>
<p><span class="Bold">3. Diagnosis of <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> — Regitine blocking test.</span></p>
<p>The test is most reliable in detecting <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> in patients with sustained <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and least reliable in those with paroxysmal <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. False-positive tests may occur in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> without <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2><span class="Bold">a. Intravenous</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.1"></a><p></p>
<h3><span class="Bold Italics">Preparation</span></h3>
<p class="First">The CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS sections should be reviewed. Sedatives, analgesics, and all other medications except those that might be deemed essential (such as digitalis and insulin) are withheld for at least 24 hours, and preferably 48-72 hours, prior to the test. Antihypertensive drugs are withheld until blood pressure returns to the untreated, hypertensive level. This test is not performed on a patient who is normotensive.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.2"></a><p></p>
<h3><span class="Bold Italics">Procedure</span></h3>
<p class="First">The patient is kept at rest in the supine position throughout the test, preferably in a quiet, darkened room. Injection of Regitine is delayed until blood pressure is stabilized, as evidenced by blood pressure readings taken every 10 minutes for at least 30 minutes.</p>
<p>Five milligrams of Regitine is dissolved in 1 mL of Sterile Water for Injection. The dose for adults is 5 mg; for children, 1 mg.</p>
<p>The syringe needle is inserted into the vein, and injection is delayed until pressor response to venipuncture has subsided.</p>
<p>Regitine is injected rapidly. Blood pressure is recorded immediately after injection, at 30-second intervals for the first 3 minutes, and at 60-second intervals for the next 7 minutes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.3"></a><p></p>
<h3><span class="Bold Italics">Interpretation</span></h3>
<p class="First">A positive response, suggestive of <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>, is indicated when the blood pressure is reduced more than 35 mmHg systolic and 25 mmHg diastolic. A typical positive response is a reduction in pressure of 60 mmHg systolic and 25 mmHg diastolic. Usually, maximal effect is evident within 2 minutes after injection. A return to preinjection pressure commonly occurs within 15-30 minutes but may occur more rapidly.</p>
<p>If blood pressure decreases to a dangerous level, the patient should be treated as outlined under OVERDOSAGE.</p>
<p>A positive response should always  be confirmed by other diagnostic procedures, preferably by measurement of urinary catecholamines or their metabolites.</p>
<p>A negative response is indicated when the blood pressure is elevated, unchanged, or reduced less than 35 mmHg systolic and 25 mmHg diastolic after injection of Regitine. A negative response to this test does not exclude the diagnosis of <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>, especially in patients with paroxysmal <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in whom the incidence of false-negative responses is high.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2"></a><p></p>
<h2><span class="Bold">b. Intramuscular</span></h2>
<p class="First">If the intramuscular test for <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> is preferred, preparation is the same as for the intravenous test. Five milligrams of Regitine is then dissolved in 1 mL of Sterile Water for Injection. The dose for adults is 5 mg intramuscularly; for children, 3 mg. Blood pressure is recorded every 5 minutes for 30-45 minutes following injection. A positive response is indicated when the blood pressure is reduced 35 mmHg systolic and 25 mmHg diastolic, or more, within 20 minutes following injection.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED</span></h1>
<p class="First"><span class="Italics">Vials</span>—  each containing 5 mg of phentolamine mesylate for injection, USP, and 25 mg of mannitol, USP, in lyophilized form.<br>   Cartons of 2…………………………………………………………….NDC 0083-6830-02</p>
<p>The reconstituted solution should be used upon preparation and should not be stored.</p>
<p>Store between 15ºC and 30ºC (59ºF-86ºF).</p>
<p>665490                                                                 
	C98-25 (Rev. 6/98)</p>
<p></p>
<p></p>
<p>Distributed by<br>Novartis Pharmaceuticals Corporation<br>East Hanover, New Jersey  07936</p>
<p></p>
<p>©1998 Novartis</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>REGITINE 		
					</strong><br><span class="contentTableReg">phentolamine mesylate injection, powder, lyophilized, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0083-6830</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>phentolamine mesylate</strong> (phentolamine) </td>
<td class="formItem"></td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem">25 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0083-6830-02</td>
<td class="formItem">2  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Novartis Pharmaceuticals Corporation</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6DB10859-2A3F-4782-AC33-94300463658F</div>
<div>Set id: 6DB10859-2A3F-4782-AC33-94300463658F</div>
<div>Version: 2</div>
<div>Effective Time: 20060510</div>
</div>
</div> <div class="DistributorName">Novartis Pharmaceuticals Corporation</div></p>
</body></html>
